SCHEMBL1807471

SCHEMBL1807471

O=C(c1ccc2ccccc2c1)N1CCC2(CC1)N[C@@H](Cc1ccccc1)C(=O)N2Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.54
DRD4 P21917 4/20 0.48
TSHR P16473 2/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.44
LMNA P02545 1/20 0.44
ACHE P22303 1/20 0.44
MAPK14 Q16539 2/20 0.43
SLC6A12 P48065 1/20 0.43
SLC6A13 Q9NSD5 1/20 0.43
RIPK1 Q13546 1/20 0.43
AKR1C1 Q04828 1/20 0.42
TPSAB1 Q15661 1/20 0.41
TPSD1 Q9BZJ3 1/20 0.41
TPSG1 Q9NRR2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1811368 0.99 NPC1 (0.53) NPC1DRD4TSHRHPGDRAB9A
SCHEMBL2934834 0.91 NPC1 (0.48) NPC1DRD4TSHRHPGDRAB9A
SCHEMBL2937853 0.87 RIPK1 (0.47) TSHRLMNARIPK1
SCHEMBL1801302 0.87 RIPK1 (0.47) TSHRLMNARIPK1
SCHEMBL4000263 0.87 RIPK1 (0.47) TSHRLMNARIPK1
SCHEMBL1803464 0.86 KMT2A (0.48) TSHRRIPK1
SCHEMBL1799019 0.86 RIPK1 (0.47) TSHRHPGDLMNARIPK1
Hydrochloric Acid SCHEMBL1800383 0.86 RIPK1 (0.47) TSHRLMNARIPK1
Hydrochloric Acid SCHEMBL1799641 0.85 RIPK1 (0.46) TSHRHPGDLMNARIPK1
SCHEMBL1801286 0.85 ALDH1A1 (0.54) TSHRLMNARIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US claimed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP claimed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7951815-B2 Substituted 1,4,8-triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2011-05-31 US disclosed
EP-1730147-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO[4,5]DECAN-2-ON COMPOUNDS FOR USE IN THE TREATMENT OF OBESITY GRUENENTHAL GMBH (DE) 2010-02-03 EP disclosed
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015784-A1 Subsitituted 1,4,8- triazaspiro [4,5]decan-2-one compounds SI, SSTR4, SLC10A2 NPC1 479/4885DRD4 1264/4885TSHR 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.